Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome
| Autor: | Benjamin Schrijver, Thomas Mandl, Paul L A van Daele, Peter Olsson, Jens C. Göpfert, Cornelia G van Helden-Meeuwsen, Zana Brkic, Willem A. Dik, Marco W.J. Schreurs, Sanne Jansen, Marjan A. Versnel, Erika Huijser |
|---|---|
| Přispěvatelé: | Immunology, Internal Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Systemic disease medicine.diagnostic_test business.industry Autoantibody medicine.disease Antiviral Agents Gastroenterology Sjogren's Syndrome Rheumatology Paired samples Internal medicine Immunoassay Interferon Type I medicine Retrospective analysis Humans Lupus Erythematosus Systemic Pharmacology (medical) Sjogren s business Patient stratification Autoantibodies Retrospective Studies Whole blood |
| Zdroj: | Rheumatology (United Kingdom), 61(5), 2156-2166. Oxford University Press |
| ISSN: | 1462-0332 1462-0324 |
| Popis: | Objectives Type I IFN (IFN-I) activation is a prominent feature of primary SS (pSS), SLE and SSc. Ultrasensitive single-molecule array (Simoa) technology has facilitated the measurement of subfemtomolar concentrations of IFNs. Here we aimed to measure IFN-α2 in serum from pSS, SLE and SSc using a Simoa immunoassay and correlate these levels to blood IFN-stimulated gene (ISG) expression and disease activity. Methods Serum IFN-α2 was measured in patients with pSS (n = 85 and n = 110), SLE (n = 24) and SSc (n = 23) and healthy controls (HCs; n = 68) using an IFN-α Simoa assay on an HD-X analyser. IFN-I pathway activation was additionally determined from serum by an IFN-I reporter assay and paired samples of whole blood ISG expression of IFI44, IFI44L, IFIT1, IFIT3 and MxA by RT-PCR or myxovirus resistance protein 1 (MxA) protein ELISA. Results Serum IFN-α2 levels were elevated in pSS (median 61.3 fg/ml) compared with HCs (median ≤5 fg/ml, P Conclusion Simoa serum IFN-α2 reflects blood ISG expression in pSS, SLE and SSc. In light of IFN-targeting treatments, Simoa could potentially be applied for patient stratification or retrospective analysis of historical cohorts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|